ES2693166T3 - Pirazolopiridina y métodos para tratar las enfermedades retinales degenerativas y la pérdida auditiva asociadas con el síndrome de Usher - Google Patents
Pirazolopiridina y métodos para tratar las enfermedades retinales degenerativas y la pérdida auditiva asociadas con el síndrome de Usher Download PDFInfo
- Publication number
- ES2693166T3 ES2693166T3 ES13849803.5T ES13849803T ES2693166T3 ES 2693166 T3 ES2693166 T3 ES 2693166T3 ES 13849803 T ES13849803 T ES 13849803T ES 2693166 T3 ES2693166 T3 ES 2693166T3
- Authority
- ES
- Spain
- Prior art keywords
- usher
- pharmaceutically acceptable
- compound
- acceptable salt
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718593P | 2012-10-25 | 2012-10-25 | |
| US201261718593P | 2012-10-25 | ||
| US201361775376P | 2013-03-08 | 2013-03-08 | |
| US201361775376P | 2013-03-08 | ||
| PCT/US2013/066938 WO2014066835A1 (en) | 2012-10-25 | 2013-10-25 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2693166T3 true ES2693166T3 (es) | 2018-12-07 |
Family
ID=50545355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13849803.5T Active ES2693166T3 (es) | 2012-10-25 | 2013-10-25 | Pirazolopiridina y métodos para tratar las enfermedades retinales degenerativas y la pérdida auditiva asociadas con el síndrome de Usher |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2912038B1 (enExample) |
| JP (1) | JP6290910B2 (enExample) |
| AU (1) | AU2013334138B2 (enExample) |
| CA (1) | CA2889537C (enExample) |
| ES (1) | ES2693166T3 (enExample) |
| IL (1) | IL238287B (enExample) |
| PL (1) | PL2912038T3 (enExample) |
| TR (1) | TR201816028T4 (enExample) |
| WO (1) | WO2014066835A1 (enExample) |
| ZA (1) | ZA201502654B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5902293B2 (ja) | 2011-04-25 | 2016-04-13 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法 |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| CA2889494C (en) * | 2012-10-25 | 2018-12-18 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| EP4178580B1 (en) | 2020-07-09 | 2025-11-05 | Usher III Initiative, Inc. | Bf 844 for use in the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2295550A3 (en) * | 2001-04-30 | 2011-12-14 | Vertex Pharmaceuticals Incorporated | Crystal structures of GSK-3beta protein and protein complexes and their use |
| ATE554087T1 (de) * | 2004-10-29 | 2012-05-15 | Abbott Lab | Neue kinaseinhibitoren |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| WO2009062118A2 (en) * | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| AU2009262068C1 (en) * | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| JP5902293B2 (ja) * | 2011-04-25 | 2016-04-13 | アッシャー・サード・イニシアティブ・インコーポレイテッド | ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法 |
| CA2889494C (en) * | 2012-10-25 | 2018-12-18 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
-
2013
- 2013-10-25 JP JP2015539867A patent/JP6290910B2/ja active Active
- 2013-10-25 ES ES13849803.5T patent/ES2693166T3/es active Active
- 2013-10-25 CA CA2889537A patent/CA2889537C/en active Active
- 2013-10-25 AU AU2013334138A patent/AU2013334138B2/en active Active
- 2013-10-25 TR TR2018/16028T patent/TR201816028T4/tr unknown
- 2013-10-25 WO PCT/US2013/066938 patent/WO2014066835A1/en not_active Ceased
- 2013-10-25 EP EP13849803.5A patent/EP2912038B1/en active Active
- 2013-10-25 PL PL13849803T patent/PL2912038T3/pl unknown
-
2015
- 2015-04-14 IL IL238287A patent/IL238287B/en active IP Right Grant
- 2015-04-20 ZA ZA2015/02654A patent/ZA201502654B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL238287B (en) | 2018-07-31 |
| AU2013334138A1 (en) | 2015-05-07 |
| CA2889537C (en) | 2017-12-12 |
| HK1214263A1 (en) | 2016-07-22 |
| ZA201502654B (en) | 2016-07-27 |
| JP2015535256A (ja) | 2015-12-10 |
| PL2912038T3 (pl) | 2019-02-28 |
| EP2912038A1 (en) | 2015-09-02 |
| AU2013334138B2 (en) | 2017-07-27 |
| JP6290910B2 (ja) | 2018-03-07 |
| TR201816028T4 (tr) | 2018-11-21 |
| EP2912038B1 (en) | 2018-08-15 |
| CA2889537A1 (en) | 2014-05-01 |
| WO2014066835A1 (en) | 2014-05-01 |
| EP2912038A4 (en) | 2016-04-20 |
| IL238287A0 (en) | 2015-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2687854T3 (es) | Pirazolopiridazinas y métodos para tratar las enfermedades degenerativas de la retina y la pérdida de audición asociada con el síndrome de Usher | |
| Yin et al. | Targeting herpes simplex virus with CRISPR–Cas9 cures herpetic stromal keratitis in mice | |
| Rathore et al. | Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops | |
| CN102164592B (zh) | 可与核黄素一起使用的增强剂制备用于在圆锥角膜的治疗中进行角膜交联的眼用组合物的用途以及相应眼用组合物 | |
| Nourinia et al. | Repeated injection of methotrexate into silicone oil-filled eyes for grade C proliferative vitreoretinopathy: a pilot study | |
| Yoon et al. | Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sjögren’s syndrome: a double-blind randomized control study | |
| KR101867791B1 (ko) | 수성 점안액 | |
| UA124698C2 (uk) | Офтальмологічний розчин | |
| ES2625534T3 (es) | Pirazolopiridazinas y métodos para el tratamiento de enfermedades degenerativas de la retina y pérdida de la audición asociadas con el síndrome de Usher | |
| KR20190013877A (ko) | 아트로핀-함유 수성 조성물 | |
| ES2772724T3 (es) | Composición farmacéutica para la prevención y el tratamiento de enfermedades del ojo seco, que contiene imatinib como principio activo | |
| ES2848977T5 (es) | Métodos de tratamiento de afecciones oculares | |
| Ye et al. | Cytoprotective effect of hyaluronic acid and hydroxypropyl methylcellulose against DNA damage induced by thimerosal in Chang conjunctival cells | |
| KR20100090278A (ko) | 목시플록사신 하이드로클로라이드 및 덱사메타손 포스페이트를 함유하는 국소용 안과 또는 이과용 용액 제제 | |
| Kim et al. | In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells | |
| KR20210072039A (ko) | 면역절제 요법 | |
| JP2017165707A (ja) | ドルゾラミドとチモロールと界面活性剤を含有する医薬組成物 | |
| JP2020055799A (ja) | 眼科組成物 | |
| US11464773B2 (en) | Nutlin-3a for treatment of proliferative vitreoretinopathy | |
| Raab et al. | Lacrimal gland abscess in a child as a rare manifestation of IgG4-related disease | |
| Cheung et al. | Infectious keratitis after ocular surface stem cell transplantation | |
| Wenk et al. | Glucocorticoid receptor binding in bovine lens. | |
| Pauly et al. | Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFNγ and toxicological profiles | |
| CN101272765A (zh) | 包含用于治疗疱疹性角膜炎的溴夫定的耐光药物组合物 | |
| Végh et al. | Presence of SARS-CoV-2 on the conjunctival mucosa in patients hospitalized due to COVID-19: Pathophysiological considerations and therapeutic implications |